Almac a leading provider of contract services to the global Pharmaceutical and Biotech industries, is pleased to announce that it has expanded its UK commercial packaging facility, with a significant investment, to provide a state-of-the-art humidity controlled blister packaging suite, complete with off-line “just in time” blister printing.
Meeting the requirements of two Japanese clients, the expansion included extensive suite modifications for processing humidity sensitive drug products; installation of a new Noack 623 blister line, a custom designed desiccant feeder and an off-line Hapa Blister-Jet printer.
The Noack blister line provides enhanced flexibility for processing larger blister sizes and innovative multi-product blister formats; it can be configured to process both thermoform and coldform materials, with maximum blister sizes of 220mm x 155mm. This versatile line facilitated the integration of a bespoke desiccant feeder that cuts, picks and places reel-fed desiccant wafers into blister pockets.
The off-line Hapa Blister-Jet augments just-in-time production. By printing country-specific artwork and variable data on each individual blister pocket, it enhances flexibility and significantly reduces stock holding.
James MacKenzie, Commercial Director at Hapa notes, “Almac represents an exciting watermark for Hapa. This partnership indicates that our innovation strategy—with high investment in just-in-time, on demand print technologies is on the right track. As order sizes continue to fall, the business case for late stage customisation continues to grow. The addition of the Blister-Jet to Almac’s portfolio extends their capability to provide rapid and efficient late stage customisation of bulk-packed blisters.” He explained that Almac’s partnership-approach to working with clients is shared by Hapa. “Their expertise,”MacKenzie added, “enables us to deliver this project quickly and efficiently.”
David Downey, Almac’s VP of Commercial Operations explains “This co-investment allows Almac to address complex packaging challenges associated with innovative drug products that require enhanced environmental controls but, importantly, also provides our partners with the option to address modest country-specific market volumes, by off-line printing blank blisters through the Hapa unit. This solution will be of significant value to those companies launching orphan and niche blistered drug products into EU and ROW markets, many of which Almac already support.”
For more information on Almac’s commercial packaging capabilities, visit http://www.almacgroup.com/commercial-services
#ENDS#
Notes to Editor
About Almac Group
‘Partnering to Advance Human Health’
The Almac Group is an established contract development and manufacturing organisation that provides an extensive range of integrated services to over 600 companies globally within the pharmaceutical and biotech sectors. The services range from R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply, IXRS® technology (IVRS/IWRS) through to commercial-scale manufacture.
The international company is a privately owned organisation that has organically grown over 30 years and now employs in excess of 3,500 highly skilled personnel. Almac is headquartered in Craigavon, Northern Ireland with operations across the US (Pennsylvania, North Carolina and California) and in Asia (Singapore and Tokyo).
Visit www.almacgroup.com, e-mail media@almacgroup.com
To read full report, please click here.
Help employers find you! Check out all the jobs and post your resume.
Meeting the requirements of two Japanese clients, the expansion included extensive suite modifications for processing humidity sensitive drug products; installation of a new Noack 623 blister line, a custom designed desiccant feeder and an off-line Hapa Blister-Jet printer.
The Noack blister line provides enhanced flexibility for processing larger blister sizes and innovative multi-product blister formats; it can be configured to process both thermoform and coldform materials, with maximum blister sizes of 220mm x 155mm. This versatile line facilitated the integration of a bespoke desiccant feeder that cuts, picks and places reel-fed desiccant wafers into blister pockets.
The off-line Hapa Blister-Jet augments just-in-time production. By printing country-specific artwork and variable data on each individual blister pocket, it enhances flexibility and significantly reduces stock holding.
James MacKenzie, Commercial Director at Hapa notes, “Almac represents an exciting watermark for Hapa. This partnership indicates that our innovation strategy—with high investment in just-in-time, on demand print technologies is on the right track. As order sizes continue to fall, the business case for late stage customisation continues to grow. The addition of the Blister-Jet to Almac’s portfolio extends their capability to provide rapid and efficient late stage customisation of bulk-packed blisters.” He explained that Almac’s partnership-approach to working with clients is shared by Hapa. “Their expertise,”MacKenzie added, “enables us to deliver this project quickly and efficiently.”
David Downey, Almac’s VP of Commercial Operations explains “This co-investment allows Almac to address complex packaging challenges associated with innovative drug products that require enhanced environmental controls but, importantly, also provides our partners with the option to address modest country-specific market volumes, by off-line printing blank blisters through the Hapa unit. This solution will be of significant value to those companies launching orphan and niche blistered drug products into EU and ROW markets, many of which Almac already support.”
For more information on Almac’s commercial packaging capabilities, visit http://www.almacgroup.com/commercial-services
#ENDS#
Notes to Editor
About Almac Group
‘Partnering to Advance Human Health’
The Almac Group is an established contract development and manufacturing organisation that provides an extensive range of integrated services to over 600 companies globally within the pharmaceutical and biotech sectors. The services range from R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply, IXRS® technology (IVRS/IWRS) through to commercial-scale manufacture.
The international company is a privately owned organisation that has organically grown over 30 years and now employs in excess of 3,500 highly skilled personnel. Almac is headquartered in Craigavon, Northern Ireland with operations across the US (Pennsylvania, North Carolina and California) and in Asia (Singapore and Tokyo).
Visit www.almacgroup.com, e-mail media@almacgroup.com
To read full report, please click here.
Help employers find you! Check out all the jobs and post your resume.
